Vendor – Call for Expression of Interest

AFA – Anonymous Client Testing Support (ACTS)

Expression of Interest – Clinic information system


Expressions of Interest are requested from health IT software vendors or developers to provide the first stage of a system to computerise the documentation and workflow of the Anonymous Testing Service. The ATS is one of the testing and support services offered by Action For Aids Singapore, a charity focused on prevention of HIV infection.

The overall scope of the project and scope of this first stage is defined in documentation to be provided on completion of the mutual NDA. An acceptable NDA is attached. AFA will consider accepting any suitable alternative format provided by the prospective vendor, highlighting in clear English all differences between it and the sample form. It is anticipated that phase 1 will be completed by end of August 2015.


 

The expression of interest process will consist of:

 

 

  1. A maximum 5 page document outlining the scope of the solution and a high level design approach and addressing issues outlined in the documents provided, including if needed hardware requirements, timelines and ability for completion of the additional elements of the solution, IP and escrow arrangements, and 3 relevant client references with contact details. Screen captures and architectural diagrams may be added within reason to the application in addition to the 5 pages.
  2. A separate costing estimate covering hardware (if relevant), software, integration, implementation support and adjustments following implementation and support for the initial 12 months of operation.
  3. A separate Statement about approach to provision of a product demonstration. Ability to access example test systems to provide an overview of functionality and capability would be appreciated, at either the initial evaluation or short list stage.

A short list of vendors will be requested to provide:

  1. Demonstration of the development platform providing a demonstration implementation of a few relevant portions of the main pre-testing data collection form (see attachment A), application of a decision support rule to guide the test selection decision, workflow, and production of report in excel format.
  2. Demonstration of previously developed software applications if possible.
  3. A detailed costed proposal for stage 1 with estimated effort for delivering other components subsequently.

It is anticipated that demonstrations and interviews will be conducted remotely using GoToMeeting or similar platform.

Provision of additional tender documentation will be provided on receipt of the attached Non-disclosure agreement, binding on both parties. A confidential tender briefing and question session will be held by teleconference at a date to be agreed.

The closing date for electronic submission of EOI will be 20/07/2015

Please return the NDA electronically (signed and scanned) to

Ms Norani Othman Tel +65 6254 0212 norani@afa.org.sg

Example of AFA client registration and data collection form is attached as an excel spreadsheet.

 

Youth Got Heart 2015

We are proud to be part of Youth Got Heart 2015. Since 2008, Raffles Institution’s (Year 5-6) Interact Club have been organising the annual Youth Got Heart (YGH). YGH 2015 is also marking SG50 here at Toa Payoh Hub Atrium. Drop by and find out more about AfA or to sign up as a volunteer.

About Youth Got Heart

YGH is a roadshow that connects VWOs such as yourself with youth volunteers all over Singapore!

This year, YGH will be slightly different as we are a SG50 event! This is an extremely exciting prospect for all of us and we really do hope that you can be a part of it!

New antibody suppresses HIV for 28 days after single dose

A new lab-made antibody can suppress HIV for up to 28 days after only a single dose, researchers at the Rockefeller University in New York have found.

Their work was published in the journal Nature on 8 April and was the first time that a new generation of HIV antibodies had been tested in humans.

‘We conclude that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure,’ wrote the study’s lead author, Michel Nussenzweig.

Full article

Passing of Mr Lee Kuan Yew

Action for AIDS is saddened by the death of Mr Lee Kuan Yew, our first Prime Minister. 
 
His leadership of our country and his achievements in building a secure and united nation with a focus on progress and prosperity, justice and equality for all Singaporeans will be his legacy. 
Action for AIDS joins all Singaporeans in offering Prime Minister Lee Hsien Loong and his family our sincerest condolences.
 
Prof Roy Chan
President
Action for AIDS, Singapore

XDR-TB spread person-to-person, not by failure of drug

XDR-TB spread person-to-person, not by failure of drug treatment


First published on http://www.aidsmap.com/ on 26 Feb 2015


Keith Alcorn

N Sarita Shah presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

The vast majority of people with extensively drug-resistant tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have acquired their infection from another person, not as the result of the failure of treatment for multidrug-resistant strains of tuberculosis (MDR-TB), N Sarita Shah told the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, on Wednesday.

Read more

PrEP and ART could almost eliminate HIV infection

Combining PrEP and ART could almost eliminate HIV infection, east African study finds


First published on http://www.aidsmap.com/ on 26 Feb 2015


Gus Cairns
Jared Baeten presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Jared Baeten presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Giving both pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) to heterosexual couples where one partner has HIV (serodiscordant couples) can almost eliminate the chance of infection in the HIV-negative partner, a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, yesterday has shown.

This study was a first in a number of ways. It is the first to combine the ideas of PrEP and of ‘treatment as prevention’ in a systematic and sequenced way. It is the first large study in Africa to use a ‘risk score’ specifically to target the intervention to those most at risk of HIV. And it is the first study of treatment as prevention to document near-elimination of HIV transmission not just from the HIV-positive partner in a serodiscordant couple, but also from extramarital partners. Read more

Early HIV treatment reduces risk of serious illness and death by 44%

Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows


First published on http://www.aidsmap.com/ on 26 Feb 2015


Keith Alcorn

Christine Danel presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting treatment according to World Health Organization (WHO) guidelines, results from the seven-year Temprano study show. The findings were presented on Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA.

Read more

AfA Look Back 2014

As the year draw to a close, we would like to take this chance to look back on a wonderful year, filled with activities, sweat and joy.

So here’s a huge thank you to all our volunteers, members and advocates. We couldn’t have done it without you. Let’s do it (even) better in 2015.

—————

Song – Broke for Free – Night Owl http://freemusicarchive.org/music/Broke_For_Free/Directionless_EP/

The Normal Heart (Update – Photo Album)

AFA (Action for AIDS, Singapore) presents a special, free, by invitation only screening of ‘The Normal Heart’ courtesy of HBO. The event took place on 10 Sep 2014 at Golden Village, Great World City.

Academy Award® nominee Mark Ruffalo, Matt Bomer, Taylor Kitsch, Emmy® winner Jim Parsons and Academy Award® winner Julia Roberts star in THE NORMAL HEART. Directed by Emmy® winner Ryan Murphy and written by Academy Award® nominee Larry Kramer, adapting his groundbreaking Tony Award-winning play of the same name, the drama tells the story of the onset of the HIV-AIDS crisis in New York City in the early 1980s, taking an unflinching look at the nation’s sexual politics as gay activists and their allies in the medical community fight to expose the truth about the burgeoning epidemic to a city and nation in denial.

 

 

 

 

 

 

Ruffalo portrays Ned Weeks, who witnesses first-hand a mysterious disease that has begun to claim the lives of many in his gay community and starts to seek answers. Matt Bomer plays Felix Turner, a reporter who becomes Ned’s lover. Taylor Kitsch plays Bruce Niles, a closeted investment banker who becomes a prominent AIDS activist. Jim Parsons plays gay activist Tommy Boatwright, reprising his role from the 2011 Broadway revival. Roberts plays physician Dr. Emma Brookner, a survivor of childhood polio who treats several of the earliest victims of HIV-AIDS.